Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out if an investigational drug, GSK598809 can
help people who have very recently quit smoking; the investigators want to find out if
continuing to take GSK598809 over six weeks can help prevent smokers from relapsing. To
relapse means you "fall back" into smoking again after quitting. The investigators also want
to find out if GSK598809 is safe to take without causing too many side effects.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
GlaxoSmithKline Mclean Hospital National Institute on Drug Abuse (NIDA)